The study purpose was to determine if G-CSF plus doseintensive cyclophosphamide 5.25 g/m 2 , etoposide 1.05 g/m 2 and cisplatin 105 mg/m 2 (DICEP) results in superior autologous blood stem cell mobilization (BSCM) than less intensive chemotherapy. From January 1993 until May 1997, 152 consecutive patients with non-Hodgkin's lymphoma (n = 55), breast cancer (n = 47), Hodgkin's disease (n = 14), multiple myeloma (n = 9), AML (n = 9), or other cancers (n = 18) initially underwent BSCM by one of three methods: Group 1: G-CSF alone ؋ 4 days (n = 30). Group 2: disease-oriented chemotherapy, dosed to avoid blood transfusions, followed by G-CSF starting day 7 or 8, and apheresis day 13 or 14 (n = 82). increasing for a variety of cancers, not all patients mobilize sufficient autologous blood stem cells (ABSC) to receive this therapy safely.
increasing for a variety of cancers, not all patients mobilize sufficient autologous blood stem cells (ABSC) to receive this therapy safely. 1 An additional concern, albeit still of controversial significance, is tumor contamination of the autograft. Current in vitro purging techniques unfortunately result in significant ABSC loss from the autograft, and only treat the graft, not the patient. 1, 2 Tumor cytoreduction in the patient is as important as in the autograft since survival following HDCT and ASCT correlates with tumor bulk. 3 We began using dose-intensive cyclophosphamide, etoposide and cisplatin (DICEP) chemotherapy in 1995 to treat multiple myeloma and poor prognosis (primary refractory, bulky and/or marrow-positive relapsed) lymphoma patients prior to ABSC collection. Initially, we used DICEP for antitumor therapy, but quickly found it mobilized stem cells as well. DICEP is a well studied, intensive, but non-myeloablative regimen with acceptable treatment-related morbidity and mortality rates. [4] [5] [6] It is very closely related to a common 'high-dose' regimen used with ASCT for Hodgkin's and non-Hodgkin's lymphoma called CBV (cyclophosphamide 6 g/m 2 , BCNU 300 mg/m 2 and etoposide 750 mg/m 2 ). 3, 7 DICEP plus G-CSF has previously been reported to mobilize blood stem cells. [8] [9] [10] Demirer and colleagues found C 4 g/m 2 , E 600 mg/m 2 and P 105 mg/m 2 to be superior to cyclophosphamide 4 g/m 2 + G-CSF (CD34 + yield 3.32 vs 1.88 ϫ 10 6 /kg) in a retrospective analysis. 9 Jennis and colleagues reported on 80 patients who underwent C 5 g/m 2 , E 1500 mg/m 2 , and P 120 mg/m 2 plus G-CSF. 10 In a median of two apheresis procedures this regimen yielded excellent quantities of CD34 + cells (median of 15.8 ϫ 10 6 /kg) with efficient hematopoietic engraftment. The doses we chose were higher than those studied by Schwartzberg et al 8 and Demirer et al 9 in an attempt to improve anti-cancer effect, but slightly lower than those reported by other investigators [4] [5] [6] 10 in order to avoid thrombocytopenia at the time of apheresis. We observed that DICEP and G-CSF seemed to mobilize ABSC more effectively than our previous mobilization regimens. The purposes of this retrospective study were: (1) to determine if DICEP and G-CSF could mobilize larger numbers of ABSC than less intensive chemotherapy and G-CSF; (2) to determine what other factors were associated with the ability to mobilize ABSC; and (3) to determine how frequently DICEP could result in the collection of a tumorfree autograft.
Patients and methods

Patients
All 152 patients studied signed informed consent prior to autologous blood stem cell mobilization (BSCM) and ASCT. Sufficient data existed concerning DICEP to justify its use outside of another phase II clinical trial. This issue was discussed with our Ethics Committee. Data were prospectively collected on these DICEP patients as a quality assurance project.
Autologous BSCM and transplantation was first performed at our center in 1993. Data on the initial 152 consecutive patients who underwent BSCM between January 1993 and May 1997 were analyzed. Patient characteristics are summarized in Table 1 . These patients were divided into one of three groups depending on whether their initial method of BSCM was G-CSF alone (Group 1, n = 30), moderately intensive, disease-specific chemotherapy plus G-CSF (Group 2, n = 82), or DICEP plus G-CSF (Group 3, n = 40). The three groups differed in gender, diagnosis, and frequency of tumor infiltration of bone marrow (all P Ͻ 0.001). These differences reflect changes in our practice pattern over time. For example, G-CSF alone was used for BSCM during 1993 and 1994, but chemotherapy plus G-CSF has more commonly been used since 1995. Also in 1995 we started performing ASCT for breast cancer.
Autologous blood stem cell mobilization and collection
Group 1 patients received G-CSF 300 g (Ͻ60 kg) or 480 g (Ͼ60 kg) s.c. daily for 4 days. The chemotherapy for Group 2 patients was dosed to produce short-duration neutropenia and thrombocytopenia which would not require platelet transfusion (see Table 2 ). Before combining Group 2 patients together, we analyzed them by chemotherapy regimen and found no evidence that any one regimen was significantly better or worse at mobilizing blood stem cells. Group 2 patients received daily G-CSF 300 g (Ͻ70 kg) or 480 g (Ͼ70 kg) s.c. starting day 7 or 8, and underwent apheresis at day 13 or 14. Group 3 patients (n = 40) received daily cyclophosphamide 1.75 g/m 2 , etoposide Peripheral blood CD34 + (PB CD34 + ) cell counts were monitored each morning starting 1 day prior to the planned apheresis day. For Group 2 and 3 patients, apheresis took place when the PB CD34
+ count was Ͼ10 ϫ 10 6 /l, and the WBC was Ͼ5 ϫ 10 9 /l. All patients underwent large volume apheresis via a double lumen central venous apheresis catheter inserted on a short-term basis, specifically for stem cell collection. The apheresis was monitored by CD34 + counts every 4 litres until target CD34 + yields were obtained. Apheresis was discontinued for: (1) target CD34 + yield, (2) platelet counts dropping below 40 ϫ 10 9 /l, (3) complications such as bleeding or citrate toxicity, or (4) decreasing CD34 + cell collection per litre apheresis during the procedure to levels deemed unsatisfactory to continue. Apheresis was performed with a continuous flow cell separator (CobeSpectra, Cobe Canada, Scarborough, Ontario) processing 5-30 l of blood/day at flow rates of 50-80 ml/min without significant differences in technique between the three groups. The procedure took place approximately 24 h after the last dose of G-CSF.
Blood stem cell cryopreservation
Blood stem cells were volume adjusted to a final concentration of Ͻ3 ϫ 10 8 mononuclear cells/ml. An equal volume of tissue culture medium TC 199, 5% albumin and 20% dimethylsulfoxide (DMSO) was mixed with the apheresis product to yield a final concentration of 10% DMSO. The final suspension was transferred into freezing bags and frozen to Ϫ90°C using a Kryo 10 Model 10-16 programmable controlled-rate freezer, and stored in liquid nitrogen at Ϫ196°C following standard methods.
113 Table 2 Group 2 
Flow cytometric quantitation of CD34 + cells and assay for tumor cells
For daily monitoring of PB CD34
+ cell counts, 100 l of whole blood were incubated with CD45-FITC (KC56; Coulter, Hialeah, FL, USA) and CD34-PE (HPCA-2; Becton Dickinson, San Jose, CA, USA) for 10 min at room temperature. The samples were lysed using the Multi-Qprep system (Coulter) and 100 l of Flow Count beads (Coulter) were added to each tube. Samples were analyzed immediately. CD34
+ cell counts were monitored during apheresis by incubating the antibodies listed above with 10 l of well mixed product from the collection bag for 10 min at room temperature. Red cells were lysed with 1 ml of Ortho-mune Lysing Reagent (Ortho Diagnostic Systems, Raritan, NJ, USA). Flow cytometric analysis was performed on an EPICS XL-MCL (Coulter) using a modified protocol. 11, 12 The status of the bone marrow was determined by combining cytomorphologic and histologic features of the marrow aspirates and trephine biopsies, respectively. In addition, samples of the marrow aspirate as well as apheresis product were analyzed to look for minimal residual disease using multiparameter flow cytometry in cases of NHL and myeloma. The detection of any number of cells showing immunophenotypic evidence of light chain restriction or expressing an abnormal immunophenotype was considered to represent involvement by cancer. Samples demonstrating immunophenotypic evidence of clonal disease were further investigated and compared to the immunophenotype of the respective diagnostic tissue to determine if they represented the same proliferative process. Nine autografts were processed by positive CD34 selection (Ceprate System, CellPRO, Bothell, WA, USA). These nine patients were either in BSCM Group 3 (n = 6) or Group 2 (n = 3), and five had detectable cancer in their marrows. For these nine patients, tumor contamination of the apheresis product was evaluated prior to CD34 + selection.
Autologous stem cell transplantation
The high-dose chemotherapy regimens varied according to disease. Seventy-five percent of patients received either melphalan alone, melphalan plus TBI, or cyclophosphamide, mitoxantrone and vinblastine. Daily G-CSF 300 (Ͻ70 kg) or 480 (Ͼ70 kg) g/day s.c. from day +7 until ANC Ͼ 1.5 was used for consecutive patients starting in 1995. Transfusion support following DICEP and ASCT consisted of 2 units of irradiated RBCs for Hb Ͻ80 g/l, and 6 units irradiated random donor platelets for platelet counts Ͻ20 ϫ 10 9 /l.
Statistics
Comparisons between the three mobilization groups: The Kruskal-Wallis rank sum test was used to test differences in patient age, weight, PB CD34 + count on the morning of the first apheresis, the total volume of apheresis per patient, CD34
+ cell yield/l apheresis, and the total number of CD34 + cells collected per kilogram. The 2 test was used to test differences in patient gender and the number of patients who had Ͼ2 ϫ 10 6 CD34 + cells/ kg collected in a single apheresis. Fisher's exact test was used to test differences in patient characteristics (diagnosis, tumor positive marrow, prior melphalan or mitomycin-C, two plus prior chemotherapy regimens), and the number of patients who had inadequate BSCM for apheresis and ASCT.
Analysis of BSCM (PB CD34
+ counts on first apheresis morning): To stabilize variances and result in a nearly nor-mal distribution, logarithmic transformation was made for PB CD34
+ counts on the first apheresis morning. Univariate analysis was conducted first, using analysis of variance in conjunction with simple regression, for the following potential predictors of BSCM: (1) BSCM group; (2) 0-1 vs 2+ prior chemotherapy regimens; (3) prior melphalan or mitomycin-C; (4) marrow infiltration with tumor; (5) gender; (6) age; (7) diagnosis; (8) prior radiotherapy. Multiple regression was then used to study the effect of a predictor with other variables being simultaneously controlled.
Analysis of time to engraftment by CD34
+ cell dose: A multivariate analysis was performed to determine which of the following factors predicted engraftment: CD34
+ cell dose/kg, mobilization group, high-dose conditioning regimen and disease.
Results
Relationship between PB CD34
+ count and CD34 + yields per litre apheresis Direct linear relationships were found between the morning PB CD34
+ cell count and the CD34 + cell yield per litre on the first day of apheresis (Figure 1) , and between the PB CD34 + count and CD34 + cells collected/kg that day (Figure 2 ).
CD34
+ cell mobilization By univariate analysis, factors predictive of superior BSCM (defined as high PB CD34
+ count on the first apheresis morning) for all 152 patients were: (1) diagnosis other than AML (P = 0.0002), (2) mobilization group (Group 3 better than 2 better than 1, P Ͻ 0.0001), (3) no prior treatment with melphalan or mitomycin-C (P Ͻ 0.0001), and (4) less than two prior chemotherapy regimens (P = 0.031). These four factors continued to be significantly associated with BSCM by multivariate analysis. Age, gender, prior radiotherapy, and marrow infiltration with tumor were not found to be related to BSCM by either univariate or multivariate analysis. Even after controlling for diagnosis, prior melphalan or mitomycin-C, and number of prior chemotherapy regimens in multivariate analysis, mobilization Group 3 yielded a PB CD34 + count of 6.4-fold greater (95% CI = 3.5-11.7) than Group 1, and 3.1-fold greater (95% CI = 1.8-5.4) than Group 2.
The results of this multivariate analysis could be criticized because of patient heterogeneity among the three mobilization groups. Therefore, the data were re-analyzed only including patients with multiple myeloma (n = 9), Hodgkin's disease (n = 14), and non-Hodgkin's lymphoma (n = 55) since these diagnoses were represented in each of the three mobilization groups. Following multivariate analysis of these 78 patients, prior melphalan (P = 0.007), BSCM Group 3 vs 2 (P = 0.002) and Group 2 vs 1 (P Ͻ 0.001) continued to independently predict BSCM, while two or more prior chemotherapy regimens was no longer significant (P = 0.15).
Additional support for superior BSCM with DICEP compared to less intensive chemotherapy + G-CSF is the fact that three of five patients who failed to mobilize sufficient CD34 + cells for apheresis and ASCT with a Group 2 regimen (PB CD34 + counts 10 ϫ 10 6 /l), had better BSCM with DICEP + G-CSF, and were then able to undergo HDCT and ASCT. The PB CD34
+ counts ( ϫ 10 6 /l) on the first 115 apheresis morning increased from 5 to 11, 7 to 19, and 6 to 43 respectively, for these three patients following BSCM with Group 2 and then Group 3 regimens. This occurred despite our general experience that a second attempt at BSCM using the same regimen within 1-2 months of the first attempt typically results in poorer BSCM on the second occasion.
Tumor cell contamination of autograft
Eleven of the 15 (73%) Group 3 patients (NHL = 8, MM = 6, HD = 1) who had cancer cells detected in marrow samples prior to DICEP, had negative marrows and apheresis products post-DICEP. One additional patient who had high-risk NHL in first partial remission following four courses of CHOP, was found to have an apheresis product positive for lymphoma after BSCM with a Group 2 regimen (cyclophosphamide 2 g/m 2 , adriamycin 50 mg/m 2 and vincristine 2 mg day 1, and prednisone 100 mg days 1-5). This patient then underwent BSCM with DICEP + G-CSF which resulted in a marrow and apheresis product free of lymphoma by morphology and flow cytometry.
Influence of CD34
+ cell dose on hematopoietic recovery post-ASCT
By multivariate analysis, only CD34
+ cell dose/kg was independently predictive of time to neutrophil and platelet engraftment; mobilization group was not. Group 3 patients who underwent ASCT (n = 37) had a median CD34
+ cell dose infused of 16.0 ϫ 10 6 /kg (range 1.8-127.0), and experienced median engraftment times of 11 days to ANC Ͼ 0.5 ϫ 10 9 /l (range 8-15), 11 days to platelets Ͼ20 ϫ 10 9 /l (range 9-38), and 17 days to platelets Ͼ100 ϫ 10 9 /l (range 10-381+).
Toxicity of DICEP + G-CSF
Patients in Group 3 experienced much more treatmentrelated toxicity than patients in Groups 1 or 2. All Group 3 patients required blood transfusions and hospitalization either for administration of DICEP or for treatment of febrile neutropenia. After the administration of DICEP, patients who had a spouse or other caregiver at home were frequently followed on an ambulatory basis every 1-2 days, and readmitted to an inpatient bed only if they developed febrile neutropenia. With the first day of DICEP chemotherapy called day 1, the median day of neutrophil recovery Ͼ0.5 ϫ 10 9 /l was day 17 (range 15-23) and median day of platelet recovery Ͼ20 ϫ 10 9 /l was also day 17 (range 14-33). A median of 2 units RBC (0-16 units) and 2 days of platelet transfusion (1-8 days) were required for DICEP. Patients underwent apheresis post-DICEP either on day 16 (n = 1), 19 (n = 9), 20 (n = 17), 21 (n = 9), 22 (n = 1) or day 23 (n = 1). Twenty-nine patients (73%) experienced febrile neutropenia (eight patients (20%) had positive blood cultures). Mucositis and other extramedullary toxicity were generally mild. Only one patient experienced a life-threatening complication requiring intensive care support. After apheresis on day 21, this patient developed ARDS requiring mechanical ventilation. No infectious cause was found and the patient made a complete recovery. The patient had a prior episode of ARDS following a laparotomy 1 year earlier. No Group 3 patient experienced a treatment-related death; following DICEP or HDCT/ASCT. The median length of hospital stay for DICEP was 14.5 days (range 4-51).
Discussion
One important result of this study is the finding that PB CD34
+ counts correlate very well with the CD34 + cell yields per litre of apheresis. Several factors can affect the CD34 + yield per litre of apheresis in addition to the degree of BSCM including timing of apheresis relative to BSCM, operator-and machine-dependent factors, unstable interface, and total duration and volume of apheresis. These factors, as well as variability in flow cytometric determination of CD34 + counts, may contribute to an imperfect correlation between PB CD34 + counts and apheresis CD34 + yields. The PB CD34 + count is probably, therefore, a more reliable indicator of BSCM than apheresis CD34 + yields. CD34
+ cell dose/kg body weight is even more unreliable as a marker of BSCM due to the added variable of patient body weight. For these reasons, PB CD34 + counts were used as the marker for BSCM in this study. This correlation between PB CD34
+ cell count and apheresis CD34 + cell yield has also been found by other investigators, 13, 14 and suggests that PB CD34 + counts at defined times postchemotherapy or post-cytokine can be used as a measure of BSCM. This would simplify design and conduct of future BSCM studies, and potentially allow variation in the method of stem cell collection by individual centers participating in these trials. This statement is not to discount the clinical importance of the number of CD34 + cells collected, but is simply to identify the most direct endpoint when comparing different methods of BSCM.
We have not routinely measured CFU-GM, CFU-GEMM, or BFU-E on stem cell products for the past few years because we found it did not add clinically useful information to the CD34 + counts. Others have also reported that CD34 yield alone is sufficient to determine adequacy of ABSC products. 15, 16 The results of this study also suggest that DICEP plus G-CSF results in superior BSCM compared to less intensive chemotherapy plus G-CSF, or G-CSF alone. The doseresponse effect of chemotherapy on stem cell mobilization has been reported previously. 1, 9, 17, 18 This knowledge is potentially important only to those patients who may not mobilize stem cells well with less intensive regimens, or to those who might benefit from the anti-tumor effects of DICEP. Regarding the former group of patients, we identified three factors which were associated with poor BSCM; diagnosis of AML, two or more prior chemotherapy regimens, and prior treatment with melphalan or mitomycin-C. All three of these factors relate to marrow damage from chemotherapy and possibly disease. There was a trend for prior radiotherapy to be associated with poor BSCM. It is possible that a larger sample size, and analysis by percentage of marrow radiated, would have resulted in a negative association between radiotherapy and BSCM. Due to missing data, we could not analyze other factors which may have affected BSCM such as the use of repetitive cycles of G-CSF with recent chemotherapy, interval from most recent chemotherapy to BSCM, cumulative duration of uninterrupted chemotherapy prior to BSCM, time from diagnosis to BSCM, and blood counts and marrow cellularity pre-BSCM. 19, 20 Most of these additional factors also relate to treatment-related marrow damage. It can be concluded that numerous factors affect BSCM, and must be controlled in the design or analysis of BSCM trials.
The dose and duration of G-CSF used in these patients may be criticized. We did not start G-CSF the day after mobilization chemotherapy, mainly for reasons of cost. We also reasoned that if 4 days of G-CSF was sufficient for BSCM in the absence of chemotherapy, then a similarly short duration of G-CSF administration would probably be sufficient when combined with chemotherapy. Also, the dose of G-CSF (approximately 4-8 g/kg/day) may have not been optimal since others have reported a dose-response of G-CSF on BSCM up to 32 g/kg/day. 21 We cannot comment as to whether the groups may have had better BSCM if G-CSF was started earlier after chemotherapy and/or at a higher dose. This, however, does not affect the comparisons made in this study regarding chemotherapy intensity since the three groups received similar G-CSF dose and duration. If starting G-CSF earlier indeed results in superior BSCM, then the significant difference found between Group 1 and the other two groups may be conservative.
As expected, the time to hematopoietic engraftment post-ASCT depended mostly upon CD34
+ cell dose/kg rather than upon mobilization regimen. Group 3 patients had rapid engraftment post-ASCT, commensurate with their infused CD34 + cell dose. Even patients who received huge doses of CD34
+ cells (up to 127 ϫ 10 6 /kg) still required approximately 10 days to engraft neutrophils and platelets. This leads one to be skeptical that ex vivo CD34 + expansion up to this level will abolish pancytopenia unless the cells have significantly different phenotypic and biologic properties than unmanipulated blood stem cells.
We do not recommend BSCM with DICEP for all patients. It is associated with substantial toxicity and cost, and its use depends more on its effectiveness as anti-cancer therapy than its effectiveness in BSCM. Nevertheless, for selected patients it may prove to be useful cancer therapy, and at the same time mobilize ABSC very well. We have found promising early results with DICEP followed by high-dose melphalan and ASCT for refractory and bulky relapsed lymphoma patients. 22 These results need to be confirmed in a randomized trial. The three drugs in DICEP are active against a wide variety of tumor types including Hodgkin's and non-Hodgkin's lymphoma, multiple myeloma, ovarian cancer, breast cancer, testicular cancer and small round cell sarcomas. Its efficacy could be studied pre-ASCT in these cancers as well. Hopefully, new hematopoietic growth factors can prevent chemotherapy-induced myelosuppression as well as mobilize ABSC more effectively than currently available agents. 23, 24 DICEP combined with these new growth factors may not only increase the safety and feasibility of this effective cancer therapy, but may result in such effective BSCM that the collection of large numbers of ABSC may be accomplished by simple phlebotomy rather than apheresis.
